- Advertisement -

As the nation rebounds from the delta variant boom, questions swirl over the future and effectiveness of new coronavirus variants and vaccines against them.

As long as the virus that causes the COVID-19 pandemic continues to infect people, new forms will continue to emerge.


Front-line health care worker shortages, burnout due to COVID-19 vaccine mandate

However, this does not mean that the variants will come with the same frequency or become more dangerous.

- Advertisement -

last week, UK health protection agency stated that a Delta descendant named AY.4.2 was “expanding” and “increasing in frequency” in England.

In a statement to Business Insider, the US Centers for Disease Control (CDC) said Wednesday that variants at “well below 0.05%” of all sequenced viruses are still very rare, with fewer than 10 in the agency’s database so far. are reported.

“At this time … there is no evidence that sub-lineage AY4.2 affects the effectiveness of our current vaccines or therapeutics,” the CDC said.

Andrew Reid, a virus expert at Pennsylvania State University, told The Associated Press that a virus needs to adapt to its host to spread more widely, and the CDC says the delta version is twice as likely as the older versions of the virus. is contagious.

However, while the virus may be more contagious, there is no evolutionary reason for it to be more lethal.

“We’ve seen a phase of rapid evolution for the virus. It’s harvesting low-hanging fruit, but there’s not an infinite number of things it can do,” said Dr. Adam Loring, a virus and infectious disease specialist at the university. of Michigan, told the AP.

Florida’s new surgeon general: Data doesn’t support masks in school

People who are seriously ill are also less likely to socialize and spread the virus to others.

With more than half of the world’s people still uninfected, the virus is likely to infect, replicate and potentially mutate – creating new variants.

about 190 million people, or about 57% of the total population, are fully vaccinated in the US

Scientists are monitoring whether the newer types can better evade the protection offered to people through vaccination and infection, which makes the immune response less effective.

If this happens, experts may promote periodically updated vaccine formulas, as is the case with annual flu shots.

Pfizer, Inc. CEO Albert Bourla said in june That, if needed, his company could develop a new COVID-19 vaccine within 100 days.

nature told On Wednesday, Pfizer/BioNTech, makers of Moderna and AstraZeneca vaccines are “running dress rehearsals” and practicing on variants known in clinical studies.

Moderna, the publication said, is recruiting hundreds of participants to test new RNA vaccines against beta and delta variants, a combination of beta and native strains and a beta-delta multivalent vaccine.